| | | |   | | | | By Ed Silverman APStock A group of Congressional lawmakers is accusing PhRMA of providing “misleading information” in response to its questions on drug pricing. Read More | | By Ed Silverman Adobe “It doesn’t go as far as we hoped," said a trade official familiar with the compromise, "but it does open up a few options." Read More | | By Ed Silverman Alex Wong/Getty Images At issue are the numerous patents sought by drugmakers that critics say form unfair monopolies and maintain high drug prices. Read More | | Sponsor content by SUFFOLK UNIVERSITY BOSTON Pharma at the intersection of private enterprise and public interest The pharmaceutical industry is global, highly competitive, and tightly regulated. As its challenges and opportunities grow, so does its need for professionals who fully understand the legal, business, and scientific considerations involved in the drug development process. Learn how tomorrow's pharma leaders can gain that expertise with a Master of Science in Law: Life Sciences degree. | | By Matthew Herper National Institute on Aging, NIH When it comes to Biogen’s controversial Alzheimer’s drug Aduhelm, even publishing the data is steeped in drama. Read More | |
No comments